If you have a child of middle school age or older, your child has most likely already had at least one dose of the meningitis vaccine Menactra. We administer Menactra at the ages of 11 and 16, and it protects against strain groups A, C, W and Y of the bacteria meningococcus. Meningococcus is the most common cause of bacterial meningitis in adolescents and young adults in the United States. If not diagnosed and treated quickly meningitis caused by meningococcus can be deadly. A fifth strain group, group B, now has its own vaccine. Meningococcus group B (MenB) was responsible for outbreaks on college campus such as UC Santa Barbara, Princeton University, Providence College, University of Oregon, and Santa Clara University. Now that the vaccine for group B is FDA approved and recommended for high risk individuals (older teenagers and young adults) by the American Academy of Pediatrics (AAP) and the Advisory Committee for Immunization Practices (ACIP), we are pleased to offer Trumenba to our patients.
Yes, it is covered by all major insurance companies.
We recommend all our patients who are 16 years or older complete the series. The vaccine series (2 separate doses) can be started at your child’s next annual check up, or you can call (804) 282-4205 to speak with someone about scheduling a shot visit appointment.
6 months. The second dose is recommended 6 months after the 1st.
If the series is not complete before they graduate, they can come back and complete the series at our office.
No, it comes in prefilled syringes that have no natural rubber latex.
Yes, Trumenba has been tested for safety and effectiveness when given at the same visit as Menactra and Gardasil.
Yes. These two vaccines protect against different strains of meningococcus. So both are needed.
Like all vaccines, there is the potential for side effects. While many individuals may have nothing more than pain at the injection site, other possible side effects include fatigue, headaches, muscle pain or chills.